It’s only fair to share… FDA approves first treatment Gamifant (emapalumab) specifically for patients with rare and life-threatening type of immune disease The U.S. Food and Drug Administration today approved Gamifant (emapalumab) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease …